Efficacy and safety of fulvestrant combined with abemaciclib in patients with hormone receptor-positive advanced breast cancer [0.03%]
氟维司群联合阿贝西利治疗激素受体阳性晚期乳腺癌患者的疗效和安全性
Lei Su,Yunyi Du,Jingyu Yao et al.
Lei Su et al.
This study evaluated the efficacy and safety of fulvestrant combined with abemaciclib in patients with hormone receptor-positive advanced breast cancer and compared the outcomes with those reported in the MONARCH 2 trial. Forty-six patients...
Fibroblast growth factor receptor 2 mutation-guided targeted therapy with lenvatinib in sebaceous carcinoma of the external auditory canal: a case report and literature review [0.03%]
外耳道皮脂腺癌伴成纤维细胞生长因子受体2基因突变富集的仑伐替尼靶向治疗：1例报告及文献复习
RuGang Zhao,Qing Han,JuYi Wen et al.
RuGang Zhao et al.
This is the first global report of a successful case of lenvatinib treatment for a rare sebaceous carcinoma originating in the external auditory canal. The patient experienced local recurrence and pulmonary metastasis despite undergoing sur...
Comparative study of the efficacy and safety of PSOX and SOX plus sintilimab regimens as first-line treatments for advanced gastric cancer [0.03%]
比较PSOX与SOX联合信迪利单抗一线治疗晚期胃癌的疗效和安全性：一项开放性、随机Ⅱ期研究
Tao Zhang,Wenbin Yang,Chenguang Zhang et al.
Tao Zhang et al.
Advanced gastric cancer (AGC) remains associated with poor survival despite advances in multimodal treatment. Recent trials suggest that adding programmed death-1 inhibitors to chemotherapy may improve outcomes in HER2-negative AGC, but rea...
Hematopoietic progenitor kinase 1 inhibitor BGB-15025 induces apoptosis in acute myeloid leukemia cells through the cell cycle pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway signaling axis [0.03%]
造血祖细胞激酶1抑制剂BGB-15025通过细胞周期途径和MAPK/ERK途径信号轴诱导急性髓系白血病细胞凋亡
Shiyu Yang,Fenglin Li,Haihui Zhuang et al.
Shiyu Yang et al.
Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy originating from the malignant clonal proliferation of hematopoietic stem/progenitor cells and is associated with a poor prognosis. Hematopoietic progenitor kinas...
Aldehyde dehydrogenase 9A1 promotes cisplatin resistance in laryngeal squamous cell carcinoma by enhancing PTEN-induced kinase 1-Parkin-mediated mitophagy [0.03%]
醛脱氢酶9A1通过增强PTEN诱导的激酶1-Parkin介导的线粒体自噬促进喉部鳞状细胞癌顺铂抗性
Jiawei Gui,Bo Wu,Yutong Fan et al.
Jiawei Gui et al.
Cisplatin resistance remains a major challenge in laryngeal squamous cell carcinoma (LSCC) treatment. Aldehyde dehydrogenase 9A1 (ALDH9A1), a mitochondrial matrix protein, is dysregulated in various cancers, but its role in LSCC is unclear....
The evolving landscape of KRAS-targeted therapy: mechanisms of resistance and emerging strategies [0.03%]
KRAS靶向治疗的演变格局：耐药机制和新兴策略
Daniel F Pilco-Janeta,Myriam De la Cruz-Puebla
Daniel F Pilco-Janeta
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are among the most common oncogenic drivers in human cancer and are associated with poor prognosis, limited therapeutic options, and frequent resistance to standard treatments. The...
Clinical importance of the interactions between the TGF-β1/SMAD and NF-κB pathways in colorectal cancer and the study of the synergistic regulatory mechanism of the STAT3-mediated pathway [0.03%]
TGF-β1/SMAD和NF-κB信号通路在结直肠癌中的相互作用及其与STAT3介导的协同调控机制研究临床意义
Huang Chao,Haosheng Liu,Weizeng Shen
Huang Chao
This study aimed to explore the clinical significance and potential mechanisms of the transforming growth factor- β1 (TGF-β1)/small mother against decapentaplegic (SMAD) and nuclear factor kappa B (NF-κB) pathways in colorectal cancer (C...
Interferon regulatory factor 4 drives M2 macrophage polarization in lung adenocarcinoma via the absent in melanoma 2-mediated phosphoinositide 3-kinase/protein kinase B signaling pathway [0.03%]
干扰素调节因子4通过AIM2介导的磷脂酰肌醇3-激酶/蛋白激酶B信号通路驱动肺腺癌中的M2型巨噬细胞极化
Xiaoyun Zou,Qing Ji,Zhongzheng Wen et al.
Xiaoyun Zou et al.
Tumor-associated macrophages, predominant immunosuppressive components within the tumor microenvironment, critically regulate lung adenocarcinoma (LUAD) progression; however, their molecular regulatory mechanisms remain incompletely charact...
Survival advantage of bevacizumab rechallenge in recurrent ovarian cancer regardless of platinum sensitivity [0.03%]
贝伐单抗再挑战可使复发卵巢癌患者获益无论其铂敏感性如何
Ugur Ozberk,Selin Akturk Esen,Serhat Sekmek et al.
Ugur Ozberk et al.
Bevacizumab has demonstrated significant efficacy in both first-line and recurrent settings of epithelial ovarian cancer; however, evidence regarding the benefit of bevacizumab retreatment after prior exposure in real-world populations rema...
Apatinib triggers ferroptosis in gastric cancer via HDAC1/HIF1α/CA9 signaling axis [0.03%]
阿帕替尼通过HDAC1/HIF1α/CA9信号轴诱导胃癌细胞铁死亡
Lijuan Meng,Lei Cao,Yueyao Lu et al.
Lijuan Meng et al.
Gastric cancer (GC) poses significant therapeutic challenges due to frequent late-stage diagnosis and limited treatment efficacy. Although Apatinib demonstrates clinical benefits in GC, acquired resistance remains problematic. Ferroptosis i...